Aim: To estimate current real-world costs of drugs and supportive care for the treatment of
multiple myeloma in a tax-based health system. Methods: Forty-one patients were included …

Due to prolonged survival and increasing treatment costs per patient, cancer treatment
imposes an increasing burden on total healthcare expenditures. Healthcare expenditures in …

Background Multiple myeloma (MM) accounts for about 10% of hematologic malignancies,
and the 5-year survival rate of patients diagnosed with multiple myeloma has increased by …

Objectives To calculate the direct costs associated with diagnosis of multiple myeloma (MM)
in local settings and establish the extent to which it is possible to obtain real life data, that …

Aims and background Multiple myeloma is the second most common hematological cancer.
Although it accounts for only a relatively small percentage of all cancer types, the costs …

Background Multiple myeloma (MM) is the second most common hematological cancer
worldwide and has significant morbidity and mortality and is increasing in incidence. While …

Aim The goal of this research was to quantify and qualify all the costs associated with
multiple myeloma (MM) from a healthcare and societal perspective and to highlight certain …

Objectives Evaluate patient profile (demographic and clinical characteristics), healthcare
resource use (HCRU) and costs in treated multiple myeloma (MM) patients according to 1st …

Aims: To assess the real-world healthcare resource utilization (HRU) and costs associated
with different treatment regimens used in the management of patients with relapsed multiple …

e18811 Background: The economic burden of multiple myeloma (MM) has been shown to
increase with more advanced lines of therapy (LOTs). Given the rapidly evolving treatment …